Resverlogix Update

March 17, 2014

“European Patent Office Grants RVX-208 Patent Until 2027″

“Resverlogix Receives $2.5 Million for Non-Core ApoA-I Assets”

TSX Exchange Symbol: RVX

CALGARY, March 17, 2014 /PRNewswire/ – Resverlogix Corp. (“Resverlogix” or the
“Company”) (TSX: RVX) is pleased to announce today that it has received
confirmation that its European patent application covering RVX-208 has
been granted. European Patent no. 2118074 is titled “Compounds for the
prevention and treatment of cardiovascular diseases.” The patent life
will extend to February 2027.

“We are delighted to have confirmation of this news,” stated Don
McCaffrey, President and CEO of Resverlogix. “This additional patent
builds upon the growing patent estate for RVX-208, our core asset. With
a patent life out to 2027, RVX-208 now has critical protection for the
next 13 years in the important European marketplace” McCaffrey added.
In addition, Resverlogix has also filed for a fixed dose combination
patent, with Rosuvastatin, that if granted will extend the patent life
to 2033.

Resverlogix also announced that it entered into a Waiver Agreement with
RVX Therapeutics Inc. (“RVX Therapeutics”), a wholly-owned subsidiary
of Zenith Epigenetics Corp., whereby Resverlogix agreed to waive its
right under a License Agreement dated June 3, 2013 to license any
method or pharmaceutical agent within the scope of certain Licensee
Patents owned or controlled by RVX Therapeutics that may be determined
to come within the ApoA-I Therapeutic Field (as defined in the License
Agreement), and RVX Therapeutics agreed not to develop any patents
and/or compounds for any indication within the ApoA-I Therapeutic Field
for a period of five years. RVX Therapeutics agreed to pay Resverlogix
$2.5 million in cash and granted to Resverlogix a right of first
refusal for a period of three years thereafter in respect of the
license or sale of such patents and/or compounds that are determined to
come within the ApoA-I Therapeutic Field. Entering into the Waiver
Agreement generated cash for Resverlogix without impacting on its core

In unrelated news, the Company also announced that a March publication
in Cell Metabolism titled “High Density Lipoproteins and
Cerebrovascular Integrity in Alzheimer’s Disease” includes discussion
of RVX-208, Resverlogix’s small molecule ApoA-I modulator, as a
potential therapeutic for Alzheimer’s Disease (AD) (Stukas et al., 2014
Cell Metabolism 19: 1-18). Prior exploratory clinical data on the
effect of RVX-208 on plasma amyloid beta levels, performed from the
Phase Ia and Phase II ASSERT studies, is discussed. As these earlier
cardiovascular trials were not specifically designed to study
Alzheimer’s disease, efforts are being undertaken to advance an
exploratory trial in an AD patient population. The Company is planning
a Phase II Clinical Trial for the Exploratory Assessment of Alzheimer’s
Disease following Treatment with RVX-208 in Patients with Alzheimer’s
and Alzheimer’s-like Dementia of Possible Vascular Origin. The trial
will target mild to moderate Alzheimer’s disease patients.

Additionally, Resverlogix has restructured its clinical CVD program,
which will now be formally directed by Dr. Jan Johansson. The Company
would like to thank Dr. Allan Gordon for his years of service, and
wishes him great success in his future endeavors.

About RVX-208

RVX-208 is a first-in-class small molecule that inhibits BET
bromodomains. RVX-208 functions by removing atherosclerotic plaque via
reverse cholesterol transport (RCT), the natural process through which
atherosclerotic plaque is transported out of the arteries and removed
from the body by the liver. RVX-208 increases production of
Apolipoprotein A-I (ApoA-I), the key building block of functional high-density lipoprotein (HDL) particles and the type required for RCT.
These newly produced, functional HDL particles are flat and empty and
can efficiently remove plaque and stabilize or reverse atherosclerotic
disease. Analysis of recent clinical trials data showed that RVX-208
significantly reduces coronary atherosclerosis and major adverse
cardiac events in patients with CVD who have a low level of HDL and
elevated CRP, a population with unmet medical need. ApoA-I may also
exert beneficial effects in Alzheimer’s disease and Diabetes Mellitus.
RVX-208 also has anti-inflammatory effects including effects on
Interleukin-6 inhibition, vascular cell adhesion-1 and monocyte
chemotactic protein-1, factors known to be involved in atherosclerosis
and plaque stability.

About Resverlogix

Resverlogix Corp. (TSX:RVX) is a clinical stage cardiovascular company
developing compounds involving ApoA-I production. RVX-208 is a
first-in-class small molecule in development for the treatment of
diseases such as atherosclerosis, Diabetes Mellitus and Alzheimer’s
disease. RVX-208 is the first BET bromodomain inhibitor in clinical
trials. Resverlogix’s common shares trade on the Toronto Stock Exchange
(TSX: RVX). For further information please visit www.resverlogix.com. We can be followed on our blog at http://www.resverlogix.com/blog and our IR App found on Apple products iTunes and Android users (Google Play).

This news release may contain certain forward-looking information as
defined under applicable Canadian securities legislation, that are not
based on historical fact, including without limitation statements
containing the words “believes”, “anticipates”, “plans”, “intends”,
“will”, “should”, “expects”, “continue”, “estimate”, “forecasts” and
other similar expressions. In particular, this news release includes
forward looking information relating to research and development
activities and the potential role of RVX-208 in the treatment of
diseases such as atherosclerosis, Diabetes Mellitus and Alzheimer’s
disease. Our actual results, events or developments could be materially
different from those expressed or implied by these forward-looking
statements. We can give no assurance that any of the events or
expectations will occur or be realized. We can give no assurance that
any of the events or expectations will occur or be realized. By their
nature, forward-looking statements are subject to numerous assumptions
and risk factors including but not limited to those associated with the
success of research and development programs, clinical trial programs
including possible delays in patient recruitment, the regulatory
approval process, competition, securing and maintaining corporate
alliances, market acceptance of the Company’s products, the
availability of government and insurance reimbursements for the
Company’s products, the strength of intellectual property, financing
capability, the potential dilutive effects of any financing, reliance
on subcontractors and key personnel and additional assumptions and risk
factors discussed in our Annual Information Form and most recent MD&A
which are incorporated herein by reference and are available through
SEDAR at www.sedar.com. The forward-looking statements contained in this news release are
expressly qualified by this cautionary statement and are made as of the
date hereof. The Company disclaims any intention and has no obligation
or responsibility, except as required by law, to update or revise any
forward-looking statements, whether as a result of new information,
future events or otherwise.

Company Contacts:

    Donald J. McCaffrey                                            Kenneth Lebioda
    President and CEO                                              SVP Business & Corporate Development
    Resverlogix Corp.                                              Resverlogix Corp.
    Phone: 403-254-9252                                            Phone: 403-254-9252
    Email:                                                         Email:
    don@resverlogix.com   ken@resverlogix.com

SOURCE Resverlogix Corp.

Source: PR Newswire

comments powered by Disqus